主页 > 医药生命 >
【medical-news】《Stroke》新研究：二十碳五烯酸可
The finding comes from a subanalysis of JELIS (Japan EPA Lipid Intervention Study), a prospective, randomized, open-label trial involving a large cohort of patients with hypercholesterolemia (total serum cholesterol at least 6.5 mmol/L). Participants in JELIS received low-dose statin (10 mg pravastatin or 5 mg simvastatin daily) alone or with 1800 mg/day of highly purified EPA ethyl ester for approximately 5 years.
Of the 9,326 patients in the EPA group, 485 had a history of stroke, as compared with 457 of the 9,319 patients in the no-EPA group.
Dr. Kortaro Tanaka of Toyama University Hospital and colleagues found that rates of first stroke were 1.3% and 1.5% in the EPA and no-EPA groups, a nonsignificant difference. However, recurrent stroke rates were 6.8% in the EPA group versus 10.5% in the no-EPA group (p = 0.047).
The researchers note that because this trial used purified EPA instead of the fish oil used in previous studies, the preventive effects on stroke can be attributed to EPA. The exact mechanism remains unclear, however, because EPA has antihyperlipidemic, antiplatelet, anti-inflammatory and antiarrhythmic effects.
The authors found it noteworthy that "even among Japanese individuals, who have relatively high plasma EPA concentrations, further increases in EPA concentration may lead to prevention of recurrence of stroke."
Based on the many epidemiological studies of fish consumption in the US and Europe, Dr. Tanaka told Reuters Health, "the beneficial effects of EPA which became clear from our study can be applied to other nationalities."
Stroke 2008;39:2052-2058. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 NEW YORK (Reuters Health) Jul 03 - Among hypercholesterolemic patients on a low-dose statin, the addition of eicosapentaenoic acid (EPA) did not reduce the occurrence of a first stroke but did lower recurrence rates in those with a history of stroke, according to a Japanese study published in the July issue of Stroke.
纽约（路透通讯社）7月3日——根据一位日本科学家发表在7月份Stroke期刊上的论文，对于众多有着低含量抑制素的高胆固醇血症患者，二十碳五烯酸（DPA）并不能减少首次卒中的发生，但是可以降低有着卒中历史患者的再发卒中。 重新编译——这篇文献的英文读起来都很拗口，郁闷啊！
纽约（路透通讯社）7月3日——根据一位日本科学家发表在7月份Stroke上的论文，对于众多抑制素含量低的高胆固醇血症患者，二十碳五烯酸（DPA）并不能减少首次卒中的发生，但是可以降低有卒中历史患者的再发卒中。
这项发现来自JELIS（日本EPA脂质干预研究）的亚分析，这是一种预期、随机并且开放的试验，包含大量患有高胆固醇血症的患者（血清总胆固醇浓度至少为6.5 mmol/L）。JELIS的参与者单独服用低剂量的抑制素（每日10 mg的普伐他汀或者5 mg的辛伐他汀）或者每日服用1800 mg高纯度的EPA乙酯——这些药物服用将近五年。
EPA组的9326名患者中，485名拥有卒中的历史，而非EPA组的9319名患者中，有457名患者有着卒中历史。
富山大学医院的Kortaro Tanaka博士和他的同事们发现，EPA组和非EPA组的首次卒中发生率是1.3% 和1.5%，没有显著性差异。但是，EPA组的再卒中发生率为6.8%，非EPA组的再卒中发生率为10.5%(p = 0.047)。
研究者认为，由于这项试验使用的是纯EPA，而非在以往的试验中使用的是鱼油，其对于卒中的保护作用应来自于EPA。确切的保护机制仍不清楚，但是，因为EPA有着抗高血脂、抗血小板、抗炎和抗心律不齐的作用。
作者认为，值得注意的是，“即使在那些血浆EPA浓度相对较高的日本人当中，EPA浓度的进一步增加将预防卒中的再发生”。
基于许多美国和欧洲的鱼类消费，Tanaka博士告诉路透社的记者“我们的研究已经使EPA的有利效应渐渐明确，我们将推广到其他国家”。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-28 17:11
医学,生命科学网